EURETINA 2024: An overview of the SING-IMT implant with Alfonso Savastano, MD, PhD
September 30th 2024Alfonso Savastano, MD, PhD spoke about the SING-IMT implant during his interview with Ophthalmology Times Europe, which took place at the EURETINA 2024 meeting held in Barcelona, Spain, on September 19-22, 2024.
EURETINA 2024: The cooperative work of an international team
September 29th 2024Taiji Sakamoto, MD, PhD, spoke about being a board member of EURETINA and his motivations to be a part of the cooperative work that is a hallmark of EURETINA. The interview took place at the EURETINA 2024 meeting held in Barcelona, Spain, on September 19-22, 2024.
EURETINA 2024: The importance of the international retina community
September 26th 2024Carl Awh, MD, FASRS, spoke about the presence of members of the American Society of Retina Specialists (ASRS) attending the EURETINA meeting and the value of the international community of retina clinicians connecting at meetings around the globe.
ANI Pharmaceuticals completes acquisition of Alimera Sciences
September 17th 2024The acquisition strengthens the company’s rare disease segment, and adds 2 durable commercial assets, Iluvien and Yutiq with significant growth potential, expanding ANI’s foothold in strategic therapeutic area of ophthalmology.
ASRS 2024: Neurotech Pharmaceuticals update on the NT-501 device
July 26th 2024Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals Encapsulated Cell Therapy platform for the potential treatment of Macular Telangiectasia Type 2, with a projected PDUFA goal date from the FDA at the annual ASRS meeting in Stockholm, Sweden.